(Reuters) - Ampio Pharmaceuticals Inc signed a deal with an India-based drug maker to produce its experimental drug for premature ejaculation and erectile dysfunction, sending its shares up 23%.
The drug would combine Ampio's experimental drug Zertane (tramadol hydrochloride), which is being tested in a late-stage trial to treat premature ejaculation, with an erectile dysfunction drug similar to Viagra (sildenafil, Pfizer Inc).
There are currently no approved drugs in the United States to treat premature ejaculation and Ampio estimates up to 30% of males treated for premature ejaculation also suffer from erectile dysfunction.
The combination drug, Zertane-ED, would be made by Syngene, a unit of Bangalore-based Biocon Ltd, Ampio said.
Ampio's Korea-based partner Daewoong Co Ltd will finance and conduct late-stage studies in South Korea.
"We will be working with Daewoong to get the study approved by the U.S. Food and Drug Administration and in South Korea, but there is no specific timeline yet," a company spokesman told Reuters.